Catalog No.
KDE22001
Detection method
Colorimetric
Sample type
Plasma, Serum
Assay type
Quantitative
Range
0.31-5 μg/mL
Sensitivity
0.156 μg/ml
Precision
CV<20%
Recovery
80-120%
Shipping
2-8 ℃
Stability and Storage
The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
Alternative Names
BIIB-054, CAS: 2094516-02-4
Background
Cinpanemab is a human-derived monoclonal antibody directed against α-synuclein. Genetic and pathology evidence implicate this protein in the molecular pathogenesis of Parkinson's disease (PD) and other α-synucleinopathies such as dementia with Lewy bodies (DLB). In 2010, Biogen licensed cinpanemab from Neurimmune. The antibody was generated with reverse translational medicine technology from naturally occurring, presumably protective antibodies found in healthy aged donors, as were aducanumab and other antibodies in the Biogen-Neurimmune partnership. The antibody, previously known as BIIB054, binds to α-synuclein residues 1-10, with 800-fold higher affinity for aggregated over monomeric α-synuclein. The antibody inhibits α-synuclein spreading in cell-based assays, and slows pathology and motor symptoms in mice (Weihofen et al., 2019).
Facile generation of drug-like conformational antibodies specific for amyloid fibrils., PMID:40301692
Quantification of cinpanemab (BIIB054) binding to α-synuclein in cerebrospinal fluid of phase 1 single ascending dose samples., PMID:39892989
An update on immune-based alpha-synuclein trials in Parkinson's disease., PMID:39666171
Limitations and potential strategies of immune checkpoint blockade in age-related neurodegenerative disorders., PMID:39313800
Engineered Antibodies to Improve Efficacy against Neurodegenerative Disorders., PMID:38928395
Transcytosis-Driven Treatment of Neurodegenerative Disorders by mRNA-Expressed Antibody-Transferrin Conjugates., PMID:38672205
Cinpanemab in Early Parkinson Disease: Evaluation of Biomarker Results From the Phase 2 SPARK Clinical Trial., PMID:38315945
The Construction and Validation of a Novel Ferroptosis-Related Gene Signature in Parkinson's Disease., PMID:38139032
Single-neuron neurodegeneration as a degenerative model for Parkinson's disease., PMID:37721280
Analysis of clinical failure of anti-tau and anti-synuclein antibodies in neurodegeneration using a quantitative systems pharmacology model., PMID:37658103
Flow cytometric isolation of drug-like conformational antibodies specific for amyloid fibrils., PMID:37461643
Monoclonal Antibodies in Neurodegenerative Disease May Work, But They Don't Help: A Perspective from Physicians., PMID:36442210
Prasinezumab and Cinpanemab - The Perspective of a Person with Parkinson's., PMID:36373296
Trial of Cinpanemab in Early Parkinson's Disease., PMID:35921450
Evaluating dopamine transporter imaging as an enrichment biomarker in a phase 2 Parkinson's disease trial., PMID:34814867
Immunotherapies for Parkinson's Disease: Progression of Clinical Development., PMID:34042040
Phase II Dose Selection for Alpha Synuclein-Targeting Antibody Cinpanemab (BIIB054) Based on Target Protein Binding Levels in the Brain., PMID:32613752